Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 4/20 | 0.48 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
| ▸ | CCR4 | P51679 | 1/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.36 |
| ▸ | LTA4H | P09960 | 4/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6342667 | 0.99 | HTR6 (0.49) | HTR6CHRNB2CHRNA4CCR4CHRNA3 | |
| SCHEMBL6348882 | 0.96 | HTR6 (0.51) | HTR6CHRNB2CHRNA4CHRNA3CHRNB4 | |
| SCHEMBL6340543 | 0.84 | HTR6 (0.56) | HTR6CHRNB2CHRNA4CCR4CHRNA3 | |
| SCHEMBL6338391 | 0.84 | CHRNB2 (0.41) | HTR6CHRNB2CHRNA4CHRNA3CHRNB4 | |
| SCHEMBL6349132 | 0.83 | CHRNB2 (0.41) | HTR6CHRNB2CHRNA4CHRNA3CHRNB4 | |
| SCHEMBL6340349 | 0.83 | HTR6 (0.57) | HTR6CHRNB2CHRNA4CCR4CHRNA3 | |
| SCHEMBL6338654 | 0.81 | CHRNB2 (0.41) | HTR6CHRNB2CHRNA4CHRNA3CHRNB4 | |
| SCHEMBL6340769 | 0.80 | HTR6 (0.60) | HTR6CHRNB2CHRNA4CHRNA3CHRNB4 | |
| SCHEMBL6339018 | 0.80 | CHRNB2 (0.44) | HTR6CHRNB2CHRNA4CHRNA3CHRNB4 | |
| SCHEMBL6347984 | 0.80 | HTR6 (0.50) | HTR6CHRNB2CHRNA4CHRNA3CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050065185-A1 | Heterocyclylalkoxy-, -alkylthio- and -alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2005-03-24 | — | — | US | claimed |
| US-20030078286-A1 | Heterocyclylalkoxy-,-alkylthio-and -alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH | 2003-04-24 | — | — | US | claimed |
| US-20050065185-A1 | Heterocyclylalkoxy-, -alkylthio- and -alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2005-03-24 | — | — | US | disclosed |
| US-6831094-B2 | For therapy of central nervous system disorders such as anxiety, depression, motor disorders | WYETH | 2004-12-14 | — | — | US | disclosed |
| EP-1392682-A2 | HETEROCYCLYLALKOXY-, -ALKYLTHIO- AND -ALKYLAMINOBENZAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | Wyeth (US) | 2004-03-03 | — | — | EP | disclosed |
| US-20030078286-A1 | Heterocyclylalkoxy-,-alkylthio-and -alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH | 2003-04-24 | — | — | US | disclosed |
| WO-2002085853-A2 | HETEROCYCLYLALKOXY-, -ALKYLTHIO- AND -ALKYLAMINOBENZAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2002-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065185-A1 | Heterocyclylalkoxy-, -alkylthio- and -alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 ligands | HTR6, HTR3B, HTR5A | HTR6 1/4885CHRNB2 191/4885CHRNA4 184/4885 |
| US-20030078286-A1 | Heterocyclylalkoxy-,-alkylthio-and -alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 ligands | HTR6, HTR3B, HTR5A | HTR6 1/4885CHRNB2 197/4885CHRNA4 192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.